Your browser is no longer supported. Please, upgrade your browser.
Settings
ADPT [NASD]
Adaptive Biotechnologies Corporation
Index- P/E- EPS (ttm)-0.95 Insider Own1.30% Shs Outstand134.37M Perf Week7.98%
Market Cap8.73B Forward P/E- EPS next Y-1.15 Insider Trans-84.71% Shs Float128.88M Perf Month16.21%
Income-122.30M PEG- EPS next Q-0.29 Inst Own78.70% Short Float3.33% Perf Quarter26.54%
Sales92.40M P/S94.44 EPS this Y-42.00% Inst Trans-3.06% Short Ratio5.31 Perf Half Y63.17%
Book/sh5.77 P/B11.28 EPS next Y-6.50% ROA-13.10% Target Price62.17 Perf Year137.82%
Cash/sh6.23 P/C10.45 EPS next 5Y2.20% ROE-20.10% 52W Range15.19 - 66.87 Perf YTD10.08%
Dividend- P/FCF- EPS past 5Y- ROI-12.90% 52W High-2.66% Beta-
Dividend %- Quick Ratio8.60 Sales past 5Y- Gross Margin75.90% 52W Low328.51% ATR3.09
Employees453 Current Ratio8.70 Sales Q/Q0.80% Oper. Margin- RSI (14)66.73 Volatility4.44% 4.88%
OptionableYes Debt/Eq0.00 EPS Q/Q-143.60% Profit Margin- Rel Volume1.92 Prev Close65.65
ShortableYes LT Debt/Eq0.00 EarningsNov 10 AMC Payout- Avg Volume809.11K Price65.09
Recom1.60 SMA207.62% SMA5020.80% SMA20047.46% Volume1,551,073 Change-0.85%
Oct-08-20Resumed BTIG Research Buy $60
Sep-09-20Initiated Morgan Stanley Equal-Weight $42
Jun-03-20Initiated Goldman Buy $60
Jul-23-19Initiated BTIG Research Buy $46
Jul-22-19Initiated William Blair Outperform
Jul-22-19Initiated Guggenheim Buy $47
Jul-22-19Initiated Goldman Neutral $32
Jul-22-19Initiated Cowen Outperform
Jul-22-19Initiated BofA/Merrill Buy $45
Jan-12-21 08:15AM  
Jan-11-21 04:01PM  
Jan-06-21 10:53AM  
Dec-30-20 04:30PM  
08:51AM  
Dec-06-20 10:00AM  
Nov-23-20 08:00AM  
Nov-19-20 06:32AM  
Nov-13-20 08:00AM  
Nov-11-20 05:21AM  
05:00AM  
Nov-10-20 05:25PM  
05:22PM  
04:13PM  
04:10PM  
Nov-03-20 12:30PM  
Oct-28-20 05:30PM  
Oct-13-20 04:05PM  
Sep-28-20 10:52AM  
Sep-01-20 04:03PM  
Aug-11-20 01:01AM  
Aug-10-20 06:35PM  
04:05PM  
12:44PM  
08:05AM  
Aug-06-20 09:24AM  
Aug-04-20 09:30AM  
Jul-30-20 06:19AM  
Jul-28-20 06:04PM  
Jul-16-20 12:00PM  
Jul-15-20 07:47PM  
Jul-14-20 04:44PM  
Jul-09-20 04:29PM  
08:05AM  
Jun-23-20 11:54AM  
Jun-17-20 08:56AM  
Jun-15-20 10:27AM  
Jun-11-20 09:00AM  
Jun-08-20 04:03PM  
Jun-07-20 06:25AM  
May-27-20 04:03PM  
May-19-20 08:03AM  
May-18-20 02:47PM  
May-14-20 11:51AM  
May-13-20 12:31PM  
07:02AM  
May-12-20 04:03PM  
08:06AM  
May-11-20 10:57AM  
09:57AM  
May-08-20 09:09AM  
May-06-20 03:06PM  
02:50PM  
12:10PM  
08:19AM  
08:00AM  
May-05-20 12:00PM  
Apr-30-20 08:51AM  
06:39AM  
Apr-27-20 04:03PM  
Apr-20-20 08:15AM  
Apr-17-20 09:13PM  
12:40PM  
Apr-15-20 04:47PM  
08:26AM  
Apr-09-20 07:45PM  
Apr-07-20 08:35PM  
Apr-05-20 10:14AM  
Apr-03-20 10:51AM  
Apr-02-20 07:58PM  
05:50PM  
04:23PM  
04:04PM  
12:29PM  
09:34AM  
09:00AM  
Mar-27-20 02:52PM  
Mar-24-20 04:45PM  
Mar-23-20 11:06AM  
Mar-20-20 02:00PM  
01:02PM  
Feb-29-20 07:12AM  
Feb-27-20 05:54PM  
Feb-26-20 04:05PM  
Feb-21-20 10:20AM  
Feb-19-20 04:05PM  
Feb-12-20 04:05PM  
Feb-10-20 08:44AM  
Feb-03-20 11:27AM  
Jan-31-20 11:52AM  
Jan-29-20 09:50AM  
Jan-23-20 08:53PM  
Jan-22-20 08:25AM  
Jan-21-20 04:39PM  
04:02PM  
Jan-13-20 07:30AM  
Jan-08-20 07:30AM  
Dec-30-19 04:05PM  
10:04AM  
Dec-26-19 02:47PM  
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test; and Amgen to develop a therapeutic to prevent or treat COVID-19. It serves the life sciences research, clinical diagnostics, and drug discovery customers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GRIFFIN MICHELLE RENEEDirectorJan 14Option Exercise7.806,00046,8006,000Jan 15 08:00 PM
RUBINSTEIN JULIEPresidentJan 14Option Exercise6.3215,00094,80015,000Jan 15 08:00 PM
GRIFFIN MICHELLE RENEEDirectorJan 14Sale65.886,000395,2530Jan 15 08:00 PM
RUBINSTEIN JULIEPresidentJan 14Sale65.6215,000984,3410Jan 15 08:00 PM
Cohen Chad MChief Financial OfficerJan 13Option Exercise6.3250,000316,00051,000Jan 15 05:00 PM
RUBINSTEIN JULIEPresidentJan 13Option Exercise6.3215,00094,80015,000Jan 15 08:00 PM
Cohen Chad MChief Financial OfficerJan 13Sale63.4150,0003,170,2681,000Jan 15 05:00 PM
RUBINSTEIN JULIEPresidentJan 13Sale63.2215,000948,2530Jan 15 08:00 PM
Cohen Chad MChief Financial OfficerJan 12Option Exercise6.3275,000474,00076,000Jan 13 08:00 PM
RUBINSTEIN JULIEPresidentJan 12Option Exercise6.3215,00094,80015,000Jan 13 08:00 PM
Cohen Chad MChief Financial OfficerJan 12Sale62.5975,0004,694,5431,000Jan 13 08:00 PM
RUBINSTEIN JULIEPresidentJan 12Sale62.6915,000940,2810Jan 13 08:00 PM
RUBINSTEIN JULIEPresidentJan 11Option Exercise6.3215,00094,80015,000Jan 13 08:00 PM
RUBINSTEIN JULIEPresidentJan 11Sale61.1815,000917,6790Jan 13 08:00 PM
RUBINSTEIN JULIEPresidentJan 08Option Exercise6.3215,00094,80015,000Jan 11 09:00 PM
RUBINSTEIN JULIEPresidentJan 08Sale60.468,814532,8950Jan 11 09:00 PM
RUBINSTEIN JULIEPresidentJan 07Option Exercise6.3215,00094,80015,000Jan 07 07:00 PM
RUBINSTEIN JULIEPresidentJan 07Sale57.3015,000859,5000Jan 07 07:00 PM
RUBINSTEIN JULIEPresidentJan 06Option Exercise6.3215,00094,80015,000Jan 07 07:00 PM
RUBINSTEIN JULIEPresidentJan 06Sale54.8915,000823,3770Jan 07 07:00 PM
RUBINSTEIN JULIEPresidentJan 05Option Exercise6.3215,00094,80015,000Jan 07 07:00 PM
RUBINSTEIN JULIEPresidentJan 05Sale55.9915,000839,9110Jan 07 07:00 PM
DOBMEIER ERICDirectorJan 04Option Exercise6.3210,00063,20010,000Jan 06 08:00 PM
BENZENO SHARONChief Business Development OffJan 04Option Exercise6.726,77145,4756,771Jan 06 08:00 PM
RUBINSTEIN JULIEPresidentJan 04Option Exercise6.3215,00094,80015,000Jan 07 07:00 PM
RUBINSTEIN JULIEPresidentJan 04Sale57.1715,000857,4760Jan 07 07:00 PM
DOBMEIER ERICDirectorJan 04Sale57.3410,000573,3690Jan 06 08:00 PM
BENZENO SHARONChief Business Development OffJan 04Sale57.396,771388,5830Jan 06 08:00 PM
Taylor Stacy LSVP and General CounselDec 31Option Exercise7.466,53048,7207,830Dec 31 09:00 PM
RUBINSTEIN JULIEPresidentDec 31Option Exercise6.3215,00094,80015,000Dec 31 09:00 PM
Taylor Stacy LSVP and General CounselDec 31Sale57.866,530377,7971,300Dec 31 09:00 PM
RUBINSTEIN JULIEPresidentDec 31Sale57.9315,000868,8970Dec 31 09:00 PM
ROBINS CHAD MCEO and ChairmanDec 30Option Exercise0.3316,5205,4521,794,700Dec 30 09:00 PM
RUBINSTEIN JULIEPresidentDec 30Option Exercise6.3215,00094,80015,000Dec 30 09:00 PM
ROBINS CHAD MCEO and ChairmanDec 30Sale59.4416,520981,9751,778,180Dec 30 09:00 PM
RUBINSTEIN JULIEPresidentDec 30Sale59.6115,000894,2190Dec 30 09:00 PM
ROBINS CHAD MCEO and ChairmanDec 29Option Exercise0.3316,7905,5411,794,970Dec 30 09:00 PM
RUBINSTEIN JULIEPresidentDec 29Option Exercise6.3215,00094,80015,000Dec 30 09:00 PM
ROBINS CHAD MCEO and ChairmanDec 29Sale59.2816,790995,3481,778,180Dec 30 09:00 PM
RUBINSTEIN JULIEPresidentDec 29Sale60.2815,000904,1930Dec 30 09:00 PM
ROBINS CHAD MCEO and ChairmanDec 28Option Exercise0.3316,2505,3631,794,430Dec 30 09:00 PM
RUBINSTEIN JULIEPresidentDec 28Option Exercise6.3215,00094,80015,000Dec 30 09:00 PM
ROBINS CHAD MCEO and ChairmanDec 28Sale60.9516,250990,4961,778,180Dec 30 09:00 PM
RUBINSTEIN JULIEPresidentDec 28Sale61.5815,000923,7670Dec 30 09:00 PM
RUBINSTEIN JULIEPresidentDec 24Option Exercise6.3215,00094,80015,000Dec 28 07:00 PM
RUBINSTEIN JULIEPresidentDec 24Sale63.5315,000953,0150Dec 28 07:00 PM
RUBINSTEIN JULIEPresidentDec 23Option Exercise6.3215,00094,80015,000Dec 23 07:00 PM
RUBINSTEIN JULIEPresidentDec 23Sale64.2615,000963,8530Dec 23 07:00 PM
HILL NANCY LOUISEEVP, Operations & Program ManaDec 22Option Exercise0.8457,00047,88067,000Dec 23 07:00 PM
RUBINSTEIN JULIEPresidentDec 22Option Exercise6.3215,00094,80015,000Dec 23 07:00 PM
HILL NANCY LOUISEEVP, Operations & Program ManaDec 22Sale63.7157,0003,631,70210,000Dec 23 07:00 PM
RUBINSTEIN JULIEPresidentDec 22Sale63.7115,000955,7060Dec 23 07:00 PM
Pellini Michael JDirectorDec 21Option Exercise6.5525,000163,75025,000Dec 23 07:00 PM
BENZENO SHARONChief Business Development OffDec 21Option Exercise6.274172,615417Dec 23 07:00 PM
RUBINSTEIN JULIEPresidentDec 21Option Exercise6.3215,00094,80015,000Dec 23 07:00 PM
Pellini Michael JDirectorDec 21Sale60.0025,0001,500,0000Dec 23 07:00 PM
BENZENO SHARONChief Business Development OffDec 21Sale59.1441724,6610Dec 23 07:00 PM
RUBINSTEIN JULIEPresidentDec 21Sale59.4315,000891,4240Dec 23 07:00 PM
HERSHBERG ROBERTDirectorDec 15Option Exercise0.452,0009002,000Dec 16 09:00 PM
LO FRANCISChief People OfficerDec 15Option Exercise7.802,00015,6002,000Dec 16 09:00 PM
HERSHBERG ROBERTDirectorDec 15Sale55.932,000111,8560Dec 16 09:00 PM
LO FRANCISChief People OfficerDec 15Sale55.942,000111,8740Dec 16 09:00 PM
HILL NANCY LOUISEEVP, Operations & Program ManaDec 14Option Exercise0.8440,00033,60050,000Dec 16 09:00 PM
GRIFFIN MICHELLE RENEEDirectorDec 14Option Exercise7.806,00046,8006,000Dec 16 09:00 PM
HILL NANCY LOUISEEVP, Operations & Program ManaDec 14Sale59.0040,0002,360,00010,000Dec 16 09:00 PM
GRIFFIN MICHELLE RENEEDirectorDec 14Sale58.846,000353,0400Dec 16 09:00 PM
VIKING GLOBAL INVESTORS LP10% OwnerDec 14Sale55.651,000,00055,650,00029,993,708Dec 16 09:03 PM
SANG CHARLESSVP, External AffairsDec 11Option Exercise6.5550,000327,50050,000Dec 11 09:00 PM
SANG CHARLESSVP, External AffairsDec 11Sale56.1350,0002,806,5000Dec 11 09:00 PM
BOBULSKY SUSANSVP, Diagnostics, clonoSEQDec 10Option Exercise1.9825,00049,50025,000Dec 11 09:00 PM
BOBULSKY SUSANSVP, Diagnostics, clonoSEQDec 10Sale55.0025,0001,375,0000Dec 11 09:00 PM
Cohen Chad MChief Financial OfficerDec 08Option Exercise6.3230,000189,60031,000Dec 09 07:05 PM
Cohen Chad MChief Financial OfficerDec 08Sale51.2430,0001,537,2381,000Dec 09 07:05 PM
BALDO LANCEChief Medical OfficerDec 07Option Exercise7.806,25048,7506,250Dec 09 07:05 PM
BALDO LANCEChief Medical OfficerDec 07Sale50.416,250315,0880Dec 09 07:05 PM
BENZENO SHARONChief Business Development OffDec 01Option Exercise6.726,77045,4686,770Dec 02 08:00 PM
BENZENO SHARONChief Business Development OffDec 01Sale48.876,770330,8560Dec 02 08:00 PM
Taylor Stacy LSVP and General CounselNov 23Option Exercise7.032,88020,2504,180Nov 24 08:00 PM
Taylor Stacy LSVP and General CounselNov 23Sale46.312,880133,3591,300Nov 24 08:00 PM
ROBINS CHAD MCEO and ChairmanNov 19Option Exercise0.3316,6805,5041,794,860Nov 19 09:00 PM
BENZENO SHARONChief Business Development OffNov 19Option Exercise6.274162,608416Nov 23 06:05 AM
ROBINS CHAD MCEO and ChairmanNov 19Sale46.5716,680776,7411,778,180Nov 19 09:00 PM
BENZENO SHARONChief Business Development OffNov 19Sale48.8641620,3260Nov 23 06:05 AM
ROBINS CHAD MCEO and ChairmanNov 18Option Exercise0.3316,6805,5041,794,860Nov 19 09:00 PM
ROBINS CHAD MCEO and ChairmanNov 18Sale48.2816,680805,3461,778,180Nov 19 09:00 PM
ROBINS CHAD MCEO and ChairmanNov 17Option Exercise0.3316,6805,5041,794,860Nov 19 09:00 PM
ROBINS CHAD MCEO and ChairmanNov 17Sale46.1216,680769,3431,778,180Nov 19 09:00 PM
GRIFFIN MICHELLE RENEEDirectorNov 16Option Exercise7.806,00046,8006,000Nov 18 09:00 PM
HERSHBERG ROBERTDirectorNov 16Option Exercise0.452,0009002,000Nov 18 09:00 PM
LO FRANCISChief People OfficerNov 16Option Exercise7.802,00015,6002,000Nov 18 09:00 PM
GRIFFIN MICHELLE RENEEDirectorNov 16Sale47.696,000286,1350Nov 18 09:00 PM
HERSHBERG ROBERTDirectorNov 16Sale47.692,00095,3810Nov 18 09:00 PM
LO FRANCISChief People OfficerNov 16Sale47.682,00095,3510Nov 18 09:00 PM
VIKING GLOBAL PERFORMANCE LLC10% OwnerNov 11Sale49.522,500,000123,787,50030,993,708Nov 13 09:00 PM
VIKING GLOBAL INVESTORS LP10% OwnerNov 11Sale49.522,500,000123,787,50030,993,708Nov 13 09:01 PM
Cohen Chad MChief Financial OfficerNov 09Option Exercise6.3230,000189,60031,000Nov 12 09:00 PM
Cohen Chad MChief Financial OfficerNov 09Sale49.1630,0001,474,7051,000Nov 12 09:00 PM
ROBINS HARLAN SChief Scientific OfficerNov 06Option Exercise6.3211,10070,15211,779Nov 06 09:00 PM
BALDO LANCEChief Medical OfficerNov 06Option Exercise7.806,25048,7506,250Nov 10 09:00 PM
ROBINS HARLAN SChief Scientific OfficerNov 06Sale51.5011,100571,629679Nov 06 09:00 PM